SEC Form 4 · accession 0001620548-26-000007
Evommune, Inc. · EVMN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Luis C. Pena
Officer — President & CEO · Director
Period of report
Jun 22, 2026
Accepted (ET)
Jun 24, 2026 · 7:59 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0002044725
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 22, 2026 | S | 7,438 | $22.71 | D | 630,458 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026.
- F2The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $22.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.